Endothelin-1 induces hypertrophy with enhanced expression of muscle-specific genes in cultured neonatal rat cardiomyocytes.

Itoh, Hiroshi; Hirata, Yukio; Hiroe, Michiaki; Tsujino, Motoyoshi; Adachi, Susumu; Takamoto, Toshihiko; Nitta, Munetaka; Taniguchi, K.; Marumo, Fumiaki

doi:10.1161/01.res.69.1.209

Cited by 465 publications

(215 citation statements)

References 25 publications

Supporting

Mentioning

197

Contrasting

Unclassified

Order By: Relevance

“…It is well known that stimulation of myocytes with hormones that activate IP 3 production, e.g. ET-1, can promote hypertrophy [150][151][152][153][154]. What is not fully understood, however, is how such hormones can affect subtle changes in Ca 2+ -dependent gene transcription inside cells that experience periodic surges of Ca 2+ during excitation-contraction coupling [155].…”

Section: Ip 3 Signaling In Ventricular Myocytesmentioning

confidence: 99%

Emerging roles of inositol 1,4,5-trisphosphate signaling in cardiac myocytes

Kockskämper

Zima

Roderick

et al. 2008

Journal of Molecular and Cellular Cardiology

172

149

View full text Add to dashboard Cite

Inositol 1,4,5-trisphosphate (IP 3 ) is a ubiquitous intracellular messenger regulating diverse functions in almost all mammalian cell types. It is generated by membrane receptors that couple to phospholipase C (PLC), an enzyme which liberates IP 3 from phosphatidylinositol 4,5-bisphosphate (PIP 2 ). The major action of IP 3 , which is hydrophilic and thus translocates from the membrane into the cytoplasm, is to induce Ca 2+ release from endogenous stores through IP 3 receptors (IP 3 Rs). Cardiac excitation-contraction coupling relies largely on ryanodine receptor (RyR)-induced Ca 2+ release from the sarcoplasmic reticulum. Myocytes express a significantly larger number of RyRs compared to IP 3 Rs (∼100:1), and furthermore they experience substantial fluxes of Ca 2+ with each heartbeat. Therefore, the role of IP 3 and IP 3 -mediated Ca 2+ signaling in cardiac myocytes has long been enigmatic. Recent evidence, however, indicates that despite their paucity cardiac IP 3 Rs may play crucial roles in regulating diverse cardiac functions. Strategic localization of IP 3 Rs in cytoplasmic compartments and the nucleus enables them to participate in subsarcolemmal, bulk cytoplasmic and nuclear Ca 2+ signaling in embryonic stem cell-derived and neonatal cardiomyocytes, and in adult cardiac myocytes from the atria and ventricles. Intriguingly, expression of both IP 3 Rs and membrane receptors that couple to PLC/IP 3 signaling is altered in cardiac disease such as atrial fibrillation or heart failure, suggesting the involvement of IP 3 signaling in the pathology of these diseases. Thus, IP 3 exerts important physiological and pathological functions in the heart, ranging from the regulation of pacemaking, excitation-contraction and excitation-transcription coupling to the initiation and/or progression of arrhythmias, hypertrophy and heart failure. KeywordsInositol 1,4,5-trisphosphate; Cardiac myocyte; Calcium; Inotropy; Arrhythmias; Nucleus; Hypertrophy © 2008 Elsevier Inc. All rights reserved. * Corresponding author. E-mail address: jens.kockskaemper@meduni-graz.at (J. Kockskämper).. NIH Public Access NIH-PA Author ManuscriptNIH-PA Author Manuscript NIH-PA Author Manuscript The discovery of IP 3A quarter of a century ago it was shown that D-myo inositol 1,4,5-trisphosphate (IP 3 ) releases Ca 2+ from a non-mitochondrial internal Ca 2+ store [1]. Since this hallmark discovery, IP 3 has emerged as a ubiquitous intracellular messenger, releasing Ca 2+ from stores through activation of IP 3 receptors (IP 3 Rs) in almost all eukaryotic cells. The major IP 3 -sensitive intracellular Ca 2+ store is the endoplasmic reticulum. However, IP 3 has also been shown to release Ca 2+ stored in other compartments, such as the Golgi and the nuclear envelope [2]. In addition, IP 3 Rs are present on the plasma membrane of some cell types, where they can gate Ca 2+ influx [3]. A crucial role for IP 3 -dependent Ca 2+ release has been demonstrated in many mammalian cell types, ranging from tiny platelets, where it initiates blood clottin...

show abstract

Section: Ip 3 Signaling In Ventricular Myocytesmentioning

confidence: 99%

Emerging roles of inositol 1,4,5-trisphosphate signaling in cardiac myocytes

Kockskämper

Zima

Roderick

et al. 2008

Journal of Molecular and Cellular Cardiology

172

149

View full text Add to dashboard Cite

show abstract

“…Gi (Sekiguchi et al, 1999) regulate the heterotrimeric G-protein Gq (see Table 1). Gq-coupled receptor agonists shown to induce hypertrophy in NRVM include norepinephrine (NE), angiotensin II (Ang II), endothelin-1 (ET-1), thrombin, lysophosphatidic acid (LPA) and prostaglandin F2a (PGF2a) (Simpson et al, 1982;Sadoshima and Izumo, 1993a;Ito et al, 1991;Glembotski et al, 1993;Goetzl et al, 2000;Adams et al, 1996). The activated alpha subunit of Gq directly stimulates phospholipase (PLC), catalyzing the hydrolysis of phosphatidylinositol bisphosphate (PIP 2 ).…”

Section: Gq-signaling Pathways In Cardiomyocyte Hypertrophymentioning

confidence: 99%

G-proteins in growth and apoptosis: lessons from the heart

2001

View full text Add to dashboard Cite

The acute contractile function of the heart is controlled by the e ects of released nonepinephrine (NE) on cardiac adrenergic receptors. NE can also act in a more chronic fashion to induce cardiomyocyte growth, characterized by cell enlargement (hypertrophy), increased protein synthesis, alterations in gene expression and addition of sarcomeres. These responses enhance cardiomyocyte contractile function and thus allow the heart to compensate for increased stress. The hypertrophic e ects of NE are mediated through Gq-coupled a 1 -adrenergic receptors and are mimicked by the actions of other neurohormones (endothelin, prostaglandin F 2a angiotensin II) that also act on Gq-coupled receptors. Activation of phospholipase C by Gq is necessary for these responses, and protein kinase C and MAP kinases have also been implicated. Gq stimulated cardiac hypertrophy is also evident in transgenic mouse models. In contrast, stimulation of G s -coupled b-adrenergic receptors or G i -coupled receptors do not directly e ect cardiomyocyte hypertrophy. Apoptosis is also induced by G-protein-coupled receptor stimulation in cardiomyocytes. Sustained or excessive activation of either Gq-or Gs-signaling pathways results in apoptotic loss of cardiomyocytes both in vitro and in vivo. Apoptosis is associated with decreased ventricular function in the failing heart. Cardiomyocytes provide an ideal model system for understanding the basis for G-protein mediated hypertrophy and apoptosis, and the mechanisms responsible for the transition from compensatory to deleterious levels of signaling. This information may prove critical for designing interventions that prevent the pathophysiological consequences of heart failure. Oncogene (2001) 20, 1626 ± 1634.

show abstract

“…Several lines of evidence suggest that ET-1 functions in a paracrine͞autocrine manner in cardiac hypertrophy. In cell cultures of cardiomyocytes, ET-1 induces hypertrophy as assessed by cell size, increased myofibrillogenesis, and transcriptional changes associated with cardiac hypertrophy such as expression of atrial natriuretic factor (3,4). Of note, in these studies the concentrations of ET-1 required to produce hypertrophy were 10 Ϫ7 to 10 Ϫ9 M, far greater than those encountered in plasma (10 Ϫ12 to 10 Ϫ13 M) (5).…”

mentioning

confidence: 93%

Mice with cardiomyocyte-specific disruption of the endothelin-1 gene are resistant to hyperthyroid cardiac hypertrophy

Shohet

Kisanuki

Zhao

et al. 2004

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

Endothelin 1 (ET-1), a potent vasoconstrictor peptide expressed by endothelium, is also produced in the heart in response to a variety of stresses. It induces hypertrophy in cultured cardiac myocytes but only at concentrations far greater than those found in plasma. We tested whether ET-1 generated by cardiac myocytes in vivo is a local signal for cardiac hypertrophy. To avoid the perinatal lethality seen in systemic ET-1-null mice, we used the Cre͞loxP system to generate mice with cardiac myocyte-specific disruption of the ET-1 gene. We used the ␣-myosin heavy chain promoter to drive expression of Cre and were able to obtain 75% reduction in ET-1 mRNA in cardiac myocytes isolated from these mice at baseline and after stimulation, in vivo, for 24 h with tri-iodothyronine (T3). Necropsy measurements of cardiac mass indexed for body weight showed a 57% reduction in cardiac hypertrophy in response to 16 days of exogenous T3 in mice homozygous for the disrupted ET-1 allele compared to siblings with an intact ET-1 gene. Moreover, in vivo MRI showed only a 3% increase in left ventricular mass indexed for body weight in mice with the disrupted allele after 3 weeks of T3 treatment versus a 27% increase in mice with an intact ET-1 gene. A reduced hypertrophic response was confirmed by planimetry of cardiac myocytes. We conclude that ET-1, produced locally by cardiac myocytes, and acting in a paracrine͞autocrine manner, is an important signal for myocardial hypertrophy that facilitates the response to thyroid hormone. C ardiac hypertrophy is characterized by an increase in myocardiocyte size and is accompanied by qualitative and quantitative changes in gene expression, protein synthesis, and physiological performance (1). Cardiac hypertrophy helps to maintain cardiac output in the presence of increased demand or afterload, yet it is one of the most important predisposing risk factors for sudden death and the development of heart failure in human populations. A greater understanding of hypertrophy, and the capacity to regulate it in human disease, could have profound clinical implications.Many ligand͞receptor systems, with their specific and interwoven downstream signaling pathways, have been implicated in cardiomyocyte hypertrophy in both cell culture and intact animals (reviewed in ref.2). These include the peptide endothelin 1 (ET-1) and its receptors ET A and ET B on the cell surface of cardiomyocytes. Several lines of evidence suggest that ET-1 functions in a paracrine͞autocrine manner in cardiac hypertrophy. In cell cultures of cardiomyocytes, ET-1 induces hypertrophy as assessed by cell size, increased myofibrillogenesis, and transcriptional changes associated with cardiac hypertrophy such as expression of atrial natriuretic factor (3, 4). Of note, in these studies the concentrations of ET-1 required to produce hypertrophy were 10 Ϫ7 to 10 Ϫ9 M, far greater than those encountered in plasma (10 Ϫ12 to 10 Ϫ13 M) (5). Although cardiac synthesis of ET-1 is negligible under normal circumstances, conditions that stimulate...

show abstract

Endothelin-1 induces hypertrophy with enhanced expression of muscle-specific genes in cultured neonatal rat cardiomyocytes.

Cited by 465 publications

References 25 publications

Emerging roles of inositol 1,4,5-trisphosphate signaling in cardiac myocytes

Emerging roles of inositol 1,4,5-trisphosphate signaling in cardiac myocytes

G-proteins in growth and apoptosis: lessons from the heart

Mice with cardiomyocyte-specific disruption of the endothelin-1 gene are resistant to hyperthyroid cardiac hypertrophy

Contact Info

Product

Resources

About